Press release -
Olink Genomics extends the Selector product line with optimized gene panel kits
Selector Technology™ enables multiplex amplification of thousands of genomic target fragments in a single reaction tube. The superior specificity providing close to 100% on target alignment makes the technology well suited for clinical sequencing applications. In addition, it is compatible with all next generation sequencing platforms.
The new Selector gene panel kits enrich the coding regions of genes involved in cell signaling pathways. There is also a kit for the two major genes related to hereditary breast cancer, BRCA1 and BRCA2. The BRCA1/BRCA2 assay was developed with Dr. Wigard Kloosterman and Prof Edwin Cuppen of the University Medical Center Utrecht, The Netherlands.
"We have shown that specificity (>95%) is unparalleled by any other enrichment technology and eveness of coverage is excellent for detection of heterozygous variants." says Dr. Kloosterman.
In addition to the pre-defined kits, researchers can design assays for their own genes of interest with the Selector Design Wizard, available at www.olinkgenomics.com.
Related links
Topics
- Science, technology
Categories
- brca2 gene
- brca1 gene
- cell signaling pathways
- targeted resequencing
- sample preparation
- sample enrichment
- resequencing
- next generation sequencing (ngs).
- cancer exon sequencing
- breast cancer genes
- biotechnology
- gene
- dna
Olink Genomics is a provider of innovative technology for sample preparation in next generation sequencing. Olink Genomics was founded by scientists from Uppsala University and Olink AB. Based in Uppsala, Sweden, the company's solutions will be offered to a wide range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the world.
